Drug Profile


Alternative Names: Flurbinitroxybutylester; Flurbiprofen nitroxybutylester; HCT 1026; NO-flurbiprofen

Latest Information Update: 16 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NicOx
  • Class Antidementias; Neuroprotectants; Nonsteroidal anti-inflammatories; Propionic acids; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Coronary artery restenosis; Inflammation; Osteitis deformans; Overactive bladder; Postmenopausal osteoporosis; Skin disorders; Urinary incontinence; Urticaria

Most Recent Events

  • 03 Nov 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Parkinson's disease pharmacodynamics section
  • 24 Mar 2006 No development reported - Phase-II for Osteitis deformans in United Kingdom (PO)
  • 24 Mar 2006 No development reported - Phase-II for Overactive bladder in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top